Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history – an open-label randomised trial (the EPPI trial): study protocol

Table 1 EPPI trial key secondary study outcomes

Combined	Preeclampsia and/or SGA <10th centile Preeclampsia and/or SGA <10th centile delivered <35⁺⁶ weeks Preeclampsia and/or SGA <10th centile delivered <33⁺⁶ weeks Preeclampsia and SGA <10^th centile delivered at any gestation
Maternal	Preeclampsia Severe preeclampsia Placental abruption Caesarean section delivery Antepartum haemorrhage Postpartum haemorrhage <500mls and <1000mls
Infant	SGA <10^th centile SGA <5^th centile SGA <3^rd centile Unexplained intrauterine fetal death Stillbirth Gestational age at delivery Mean birthweight Mean birthweight centile Neonatal Intensive Care Unit admission Neonatal death
Uteroplacental	Abnormal uterine artery Doppler waveform at 20 or 24 weeks Abnormal umbilical artery Doppler waveform at 20 or 24 weeks
Placental & angiogenic growth factors	soluble fms-like tyrosine kinase-1 (sFlt-1) soluble endoglin (soluble Eng) Endothelin-1 (ET-1) Placental growth factor (PLGF) soluble vascular cell adhesion molecule 1 (VCAM1)

SGA small for gestational age, all SGA measured by customised birthweight centile [46]

ISSN: 1471-2393